DelveInsight’s Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disordermarket report provides an in-depth understanding of CDKL5 Deficiency Disorder, historical and forecasted epidemiology, and CDKL5 Deficiency Disorder market trends in the 7MM. The report also examines existing CDKL5 Deficiency Disorder treatment practices/algorithms, market drivers, market barriers, and unmet medical requirements in order to identify and evaluate the market’s underlying potential.
Some of the Crucial Highlights from the CDKL5 Deficiency Disorder Market Report
-
According to DelveInsight CDKL5 Deficiency Disorder epidemiology insights, the total prevalent cases was estimated to be 16,511 in 7MM in 2020.
-
Over 1,000 CDKL5 Deficiency Disorder cases have been reported globally, according to the US National Library of Medicine.
-
According to the National Organization of Rare Disorders (NORD), the CDKL5 Deficiency Disorder prevalence between females and males is in the 4:1 ratio.
-
Among the EU5 countries, Germany has the highest number of CDKL5 Deficiency Disorder diagnosed cases while Spain has the least in 2020.
-
Soticlestat (TAK-935/OV935) by Takeda and Ovid Therapeutics is a first-in-class inhibitor of cholesterol 24-hydroxylase (CH24H) that is being studied as an anti-epileptic medication (AED).
-
Marinus Pharmaceuticals’ Ganaxolone is an allosteric modulator of GABAA receptors that works by attaching to places other than the benzodiazepine binding site.
-
Several pharmaceutical companies such as Takeda/ Ovid Therapeutics, Marinus Pharmaceuticals and others are developing novel therapies for CDKL5 Deficiency Disorder treatment.
To learn more, request sample @ CDKL5 Deficiency Disorder
The CDKL5 Deficiency Disorder market report covers current treatment practices, emerging drugs, CDKL5 Deficiency Disorder market share of individual therapies, as well as current and CDKL5 Deficiency Disorder market size from 2018 to 2030, segmented by seven major markets.
CDKL5 Deficiency Disorder: Overview
CDKL5 Deficiency Disorder (CDD) is a rare developmental epileptic encephalopathy (DEE) caused by changes (mutations) in the CDKL5 gene. CDD has been classified as a DEE because the genetic change causes both epileptic activity and severe developmental impairment.
The CDKL5 Deficiency Disorder symptoms include epileptic seizures starting early in life, epileptic spasms often occurring without hypsarrhythmia, multiple different types of seizures, limited ability to walk, limited hand skills, lack of eye contact, constipation, sleep difficulties, intellectual disability, etc.
CDKL5 Deficiency Disorder Epidemiology Segmentation
-
CDKL5 Deficiency Disorder Total Prevalent Population
-
CDKL5 Deficiency Disorder Gender-Specific Prevalence
-
CDKL5 Deficiency Disorder Clinical Manifestation Specific Prevalence
-
CDKL5 Deficiency Disorder Diagnosed and Treatable Prevalence
CDKL5 Deficiency Disorder Treatment Landscape
Several drugs (anticonvulsant monotherapy) are indicated to manage CDKL5 Deficiency Disorder symptoms, and surgical procedures are used if medication is ineffective. Physical symptoms of CDKL5 Deficiency Disorder can often be eased and managed with a comprehensive treatment plan that includes occupational therapy, speech therapy, and visual therapy.
CDKL5 Deficiency Disorder Market
The market size of CDKL5 Deficiency Disorder was USD 6.54 million in 7MM in 2020.
Pharmaceutical companies’ extensive research and development operations with drugs in clinical trials, as well as the projected launch of TAK-935/OV935 (Takeda and Ovid Therapeutics) and Ganaxolone (Marinus Pharmaceuticals), will fuel the CDKL5 Deficiency Disorder market expansion during the forecasted period, 2021–2030.
Got queries? What is CDD disorder? Find out @ CDKL5 Deficiency Disorder Life Expectancy
CDKL5 Deficiency Disorder Pipeline Therapies and Key Companies
-
TAK-935/OV935 : Takeda and Ovid Therapeutics
-
Ganaxolone: Marinus Pharmaceuticals
Table of Contents
|
1. |
Report Introduction |
|
2. |
Executive Summary |
|
3. |
SWOT Analysis |
|
4. |
CDKL5 Deficiency Disorder Market Overview at a Glance |
|
5. |
Disease Background and Overview: CDKL5 Deficiency Disorder |
|
6. |
CDKL5 Deficiency Disorder Epidemiology and Patient Population |
|
7. |
CDKL5 Deficiency Disorder: Country-wise Epidemiology |
|
8. |
CDKL5 Deficiency Disorder Treatment and Medical Practices |
|
9. |
CDKL5 Deficiency Disorder Patient Journey |
|
10. |
CDKL5 Deficiency Disorder Key Emerging Therapies |
|
11. |
Attribute Analysis |
|
12. |
CDKL5 Deficiency Disorder: Market Size |
|
13. |
7MM CDKL5 Deficiency Disorder: Country-Wise Market Analysis |
|
14. |
CDKL5 Deficiency Disorder Market Access and Reimbursement |
|
15. |
CDKL5 Deficiency Disorder Market Drivers |
|
16. |
CDKL5 Deficiency Disorder Market Barriers |
|
17. |
Appendix |
|
18. |
Report Methodology |
|
19. |
DelveInsight Capabilities |
|
20. |
Disclaimer |
|
21. |
About DelveInsight |
For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare and Biotech Blog Posts
Related Reports
Alpha Antitrypsin Deficiency Market
Get comprehensive historical and forecast analysis of Alpha Antitrypsin Deficiency Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Grifols, Kamada, Shire, CSL Behring, Inhibrx, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/